EMD Serono at ASCO 2020

Virtual Scientific Program of the American Society of Clinical Oncology May 29-31, 2020

Select ASCO 2020 Abstracts

Title Lead Author Abstract # Presentation Date / Time
BAVENCIO (avelumab)
     
Maintenance avelumab + best supportive care (Ave + BSC) vs BSC alone after platinum-based first-line (1L) chemotherapy (CTx) in advanced urothelial carcinoma (aUC): results from the JAVELIN Bladder 100 phase 3 trial T Powles LBA1

Accepted for Plenary Session, Sunday, May 31 at 1 p.m.

Abstract available online at the ASCO Meeting Library from Thursday, May 28 at 5 p.m.

Association of neutrophil to lymphocyte ratio (NLR) with efficacy from JAVELIN Renal 101 MA Bilen 5061 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
Tepotinib      
Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping:  health-related quality of life (HRQoL) (VISION PRO) PK Paik 9575 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with NSCLC with METex14 skipping X Le 9556 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
Bintrafusp Alfa      
Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC) BC Cho 9558 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
DDRi      
A multicenter Phase Ib/II study of DNA-PK inhibitor peposertib (formerly M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer P  Romesser TPS4117 ASCO Meeting Library, Wednesday, May 13 at 5 p.m.
  • Our Oncology Franchise

    We understand that every person diagnosed with cancer is someone’s parent, sibling, or friend. This drives our discovery and development of medicines that matter.

    Oncology
  • Our Pipeline

    Browse the programs in our pipeline to see what we're currently working on by phase, therapeutic area and compound type.

    Global Pipeline

Julissa Viana

EMD Serono Media Contact